Active Trials

These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.

Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.

Trial name A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Type of trial Phase III
Trial ID NCT 04348656
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

This study is for people who are hospitalized for COVID-19. All study participants will get convalescent plasma (a part of blood) to see if it prevents death and reduces intubation, and to see whether people are able to leave the intensive care unit and the hospital faster.

Study team
Donald Arnold
Dr. Donald Arnold
MD
McMaster University
Trial name An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19
Type of trial Phase III
Trial ID NCT 04327388
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Ontario, British Columbia
Trial description

This study is for people who are hospitalized with severe or critical COVID-19 infection. The study compares sarilumab and placebo to see if sarilumab prevents death and impoves clinical symptoms of COVID-19.

Study team
Trial name CONCOR-KIDS: A randomized, multicentered, open-label Phase 2 clinical trial of the safety and efficacy of human Coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children
Type of trial Phase II
Trial ID NCT04377568
Health Canada Status Health Canada approved
Trial Status Pending
Location
Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, Saskatchewan
Trial description

This study is for children hospitalized with COVID-19. Study participants will know which therapy they receive, and it will be either (1) standard of care, or (2) convalescent plasma and standard of care. The study is to see if convalescent plasma improves clinical symptoms of COVID-19 and to see if it prevents death.

Study team
Dr. Julia Upton
Dr. Julia Upton
MD, MPH, Study Chair
Allergy and Immunology Department, The Hospital for Sick Children
Trial name COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (CORIPREV-LR)
Type of trial Phase III
Trial ID NCT 04321174
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, British Columbia
Trial description

This study is for people who have been in close contact with someone who has COVID-19. The study is to see if lopinavir/ritonavir can prevent COVID-19 from being transmitted.

Study team
Dr. Darrell Tan
Dr. Darrell Tan
MD, FRCPC, PhD
St. Michael’s Hospital
Trial name Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Type of trial Phase II
Trial ID NCT 04315298
Health Canada Status Health Canada approved
Trial Status Open
Location
United States, British Columbia
Trial description

This study is for people who are hospitalized for COVID-19. The study compares sarilumab to placebo to see if sarilumab improves clinical symptoms faster than placebo.

Study team
Regeneron Pharmaceuticals
Study Sponsor
.
Trial name Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections (NONTM)
Type of trial Phase II
Trial ID NCT 03331445
Health Canada Status Health Canada approved
Trial Status Open
Location
British Columbia
Trial description

This study is for people who are diagnosed with difficult bacterial and viral lung infections including COVID-19. In the case of COVID-19, the study participants will inhale nitric oxide gas to see if they have faster recovery from COVID-19, need less oxygen therapy, and need less mechanical assistance with breathing.

Study team
Dr. Jeremy Road
Dr. Jeremy Road
MD
BC Diabetes
Trial name Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution (NORS) Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection
Type of trial Phase II
Trial ID NCT 04337918
Health Canada Status Health Canada approved
Trial Status Open
Location
British Columbia, Quebec
Trial description

This study is for people who work or live with patients who have COVID-19, or who work in places that have high risk of contact with patients who have COVID-19. Study participants will either (1) take standard precautions, or (2) take standard precautions and Nitric Oxide Releasing Solution (NORS) to see if NORS prevents COVID-19 infection. Study participants who become COVID-19 positive will take NORS to see if it reduces hospitalization, oxygen therapy, or the need for machines to help with breathing.

Study team
Dr. Jeremy Road
Dr. Jeremy Road
MD
BC Diabetes
Trial name Therapeutic-dose anti-coagulation for the treatment of hospitalized patients with COVID-19: the antthrombotic therapy to ameliorate complications of COVID01 (ATTACC) trial
Type of trial Phase II | Phase III
Trial ID NCT04372589
Health Canada Status Health Canada approved
Trial Status Open
Location
British Columbia, Manitoba, Ontario, Quebec, Saskatchewan
Trial description

This study is for people who are hospitalized for COVID-19. Study participants will receive heparin or usual care, to see if heparin prevents the need for a machine to help with breathing or death.

Study team
Dr. Patrick Lawler
Dr. Patrick Lawler
MD, MPH
Peter Munk Cardiac Centre/University Health Network
Dr. Ewan Goligher
Dr. Ewan Goligher
MD, PhD
University Health Network, Toronto
Dr. Ryan Zarychanski
Dr. Ryan Zarychanski
MD, MSc, FRCPC
University of Manitoba
Trial name Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)
Type of trial Phase II
Trial ID NCT 04330690
Health Canada Status Health Canada approved
Trial Status Open
Location
Alberta, British Columbia, Ontario, Quebec
Trial description

This study is for people who are admitted in the hospital with COVID-19. The study compares 4 different treatments to prevent death and improve clinical symptoms. The study participants will know which treatment they are getting, which will be one of: (1) standard care, (2) lopinavir/ritonavir with standard care, (3) hydroxychloroquine with standard care, or (4) remdesivir with standard care.

Study team
Dr. Nelson Lee
Dr. Nelson Lee
MD
University of Alberta Hospital
Dr. Allison Mah
Dr. Allison Mah
MD
Vancouver General Hospital,
Dr. Natasha Press
Dr. Natasha Press
MD
St. Paul’s Hospital
Dr. Shane English
Dr. Shane English
MD
The Ottawa Hospital
Dr. Robert Fowler
Dr. Robert Fowler
MD
Sunnybrook Health Sciences Centre
Dr. Bryan Coburn
Dr. Bryan Coburn
MD
Toronto Western Hospital
Dr. Matthew Cheng
Dr. Matthew Cheng
MD
McGill University Health Centre-Glen Site Royal Victoria HospitalRecruiting
Dr. Alexis Turgeon
Dr. Alexis Turgeon
MD
CHU de Québec – Université Laval
Dr. Francois Lellouche
Dr. Francois Lellouche
MD
Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval
Dr. Daniel Ovekim
Dr. Daniel Ovekim
MD
Royal Jubilee Hospital
Dr. Anna Geagea
Dr. Anna Geagea
MD
North York General Hospital
Dr. Francois Lamontagne
Dr. Francois Lamontagne
MD
Centre Hospitalier de l'Université de Sherbrooke